# OnCo record plasma-cell-leukaemia (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/plasma-cell-leukaemia/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "plasma-cell-leukaemia" ;
  schema:name "Plasma cell leukaemia"@en ;
  schema:alternateName "PCL"@en, "Primary plasma cell leukaemia"@en, "Secondary plasma cell leukaemia"@en, "Leukaemic myeloma"@en ;
  schema:description "Plasma cell leukaemia is myeloma in which the cancerous plasma cells spill into the bloodstream in large numbers. It is the most aggressive plasma cell cancer and is treated urgently with several myeloma drugs at once followed by a stem cell transplant."@en ;
  schema:url <https://onco.cc/cancers/plasma-cell-leukaemia/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Plasma_cell_leukemia> ;
  schema:citation <https://en.wikipedia.org/wiki/Plasma_cell_leukemia>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/flow-cytometry-mrd/> ;
  onco:targets <https://onco.cc/targets/cd38/>, <https://onco.cc/targets/bcma/>, <https://onco.cc/targets/proteasome/>, <https://onco.cc/targets/tp53/> ;
  onco:terms <https://onco.cc/terms/high-risk-myeloma/>, <https://onco.cc/terms/tp53-mutated/>, <https://onco.cc/terms/autologous-transplant/>, <https://onco.cc/terms/leukaemia-type/>, <https://onco.cc/terms/proteasome-inhibitor/> ;
  onco:pipeline <https://onco.cc/drugs/teclistamab/>, <https://onco.cc/drugs/ciltacabtagene-autoleucel/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/carfilzomib/> ;
  onco:standardOfCare <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/carfilzomib/>, <https://onco.cc/terms/tumor-lysis-syndrome/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/melphalan/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/terms/maintenance-therapy/>, <https://onco.cc/drugs/teclistamab/>, <https://onco.cc/drugs/talquetamab/>, <https://onco.cc/drugs/ciltacabtagene-autoleucel/>, <https://onco.cc/drugs/selinexor/>, <https://onco.cc/drugs/pomalidomide/> .